Back to Resource Library
Webinar Description:This webinar will present the underpinning mechanisms driving freeze thaw applications and their implications across varied drug product containment configurations and volumes. The links between controlled freezing rates, container design, and cellular outcomes are explored by science-based research approaches taken on by industry collaborators. The outputs will support the future development of cell therapy cryopreservation configurations and options proven through a science-based approach to supplier-side process development and driven by technologies and best practices present in the cell and gene industry.
The Cryopreservation Process and Its Impact On The Consistency Of High-quality Cell Therapy ProductsAn ISCT Process & Product Development Committee WebinarPart 3 of 6 of the ISCT PPD Cryopreservation Webinar Series
Sponsored in part by:
Michael Delahaye, EngD Director of Cell Therapy BioprocessingAstraZeneca United Kingdom
Michael is the Head of Viral Vector Industrialization at the Cell and Gene Therapy Catapult and has almost 15 years of industrial experience within the cell and gene therapy sector. He leads a team of experienced scientists within the Viral Gene Delivery program, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. The team’s key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterization tools to facilitate the production of AAV based gene therapies. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture
Samuel Molina, PhD Manager, R&D Applied Life SciencesWest Pharmaceutical ServicesUnited States
Sam is the Cell and Gene Therapy SME in the Applied Life Sciences & Technology Scouting R&D organization at West. He came to West with 8 years of hands-on knowledge in primary human cell manufacturing at both academic and commercial scale, having developed processes and products for the 3D human primary cell models and immunology and cell therapy research markets
Peter Kilbride, PhD Senior Scientist, CGTCytivaUnited Kingdom
Peter is Senior Scientist at Cytiva, with a focus on running cryopreservation related projects in the Cell and Gene Therapy space. After finishing his PhD in Mathematics and Low Temperature Biology from University College London, he joined Asymptote, later GE Healthcare and Cytiva setting up and running a dedicated cryobiological lab. He is responsible both for carrying out fundamental cryobiological work, but also developing academic-based processes into cGMP compliant workflows and running external collaborations.
© 2021 ISCT. All rights reserved.
Site by eConverse Media